2026 Q2 Portfolio Activity
In 2026 Q2, Vestal Point Capital, LP maintained a portfolio of 101 distinct positions. The most significant new addition was Abbott Laboratories, now representing 2.97% of the total fund value. They heavily accumulated shares in United Therapeutics Corp, increasing the position by 480.0%. The fund also reduced its exposure to Revolution Medicines Inc by 81.1%.
Position History
hover any row below to update
Loading…
Total Positions
101
Quarter
2026 Q2
Top Holding
BMRN (8.1%)
Top 10 Concentration
50.3%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 101
Vestal Point Capital, LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BMRN
BioMarin Pharma...
|
Healthcare | 8.06% | 5.65% |
#1
1
Prev: #2
|
8.2 |
—
|
2,450,000 | 68.5% |
P
S
|
6,025,000 | $344,750,500 |
$59.65
+9.5%
|
2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
NBIX
Neurocrine Bios...
|
Healthcare | 7.40% | 4.60% |
#2
2
Prev: #4
|
7.5 |
—
|
630,000 | 50.4% |
P
S
|
1,880,000 | $316,845,800 |
$140.49
+9.2%
|
2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ABVX
Abivax SA
|
Healthcare | 7.32% | 4.67% |
#3
Prev: #3
|
6.9 |
—
|
849,443 | 56.6% |
P
S
|
2,349,443 | $313,086,774 |
$116.19
-0.2%
|
2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
UTHR
United Therapeu...
|
Healthcare | 5.51% | 1.24% |
#4
27
Prev: #31
|
5.7 |
—
|
360,000 | 480.0% |
P
S
|
435,000 | $235,696,050 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ELVN
Enliven Therape...
|
Healthcare | 4.74% | 3.56% |
#5
1
Prev: #6
|
4.9 |
—
|
750,000 | 23.1% |
P
S
|
4,000,000 | $203,000,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NRIX
Nurix Therapeut...
|
Healthcare | 4.56% | 2.82% |
#6
3
Prev: #9
|
4.3 |
—
|
1,550,000 | 23.8% |
P
S
|
8,050,000 | $195,293,000 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 3.64% | 3.02% |
#7
1
Prev: #8
|
2.0 |
—
|
-175,000 | -3.2% |
P
S
|
5,250,000 | $155,872,500 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TSHA
Taysha Gene The...
|
Healthcare | 3.09% | 2.25% |
#8
5
Prev: #13
|
3.2 |
—
|
1,415,000 | 7.9% |
P
S
|
19,415,000 | $132,216,150 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 3.00% | 3.99% |
#9
4
Prev: #5
|
1.2 |
—
|
-700,000 | -30.8% |
P
S
|
1,575,000 | $128,378,250 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABT
Abbott Laborato...
|
Healthcare | 2.97% | — |
#10
Prev: #—
|
4.7 |
—
|
1,400,000 | — |
NEW
|
1,400,000 | $127,036,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZBH
Zimmer Biomet H...
|
Healthcare | 2.82% | 0.48% |
#11
43
Prev: #54
|
4.1 |
—
|
1,210,000 | 636.8% |
P
S
|
1,400,000 | $120,526,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IRON
Disc Medicine I...
|
Healthcare | 2.65% | 1.25% |
#12
18
Prev: #30
|
4.1 |
—
|
850,000 | 121.4% |
P
S
|
1,550,000 | $113,367,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 2.60% | 1.66% |
#13
8
Prev: #21
|
3.5 |
—
|
996,535 | 27.7% |
P
S
|
4,600,000 | $111,320,000 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PODD
Insulet Corp
|
Healthcare | 2.38% | 0.30% |
#14
49
Prev: #63
|
4.0 |
—
|
619,399 | 1224.1% |
P
S
|
670,000 | $102,007,500 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
Ascendis Pharma...
|
|
Unknown | 2.34% | — |
#15
Prev: #—
|
4.4 |
—
|
375,000 | — |
NEW
|
375,000 | $100,020,000 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
AZNCF
AstraZeneca PLC
|
Unknown | 1.99% | 0.55% |
#16
34
Prev: #50
|
3.8 |
—
|
350,000 | 350.0% |
P
S
|
450,000 | $85,329,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNY
Sanofi SA
|
Healthcare | 1.99% | 1.89% |
#17
2
Prev: #15
|
3.3 |
—
|
600,000 | 42.9% |
P
S
|
2,000,000 | $85,320,000 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RVMD
Revolution Medi...
|
Healthcare | 1.97% | 6.46% |
#18
17
Prev: #1
|
0.8 |
—
|
-1,925,000 | -81.1% |
P
S
|
450,000 | $84,276,000 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCRX
BioCryst Pharma...
|
Healthcare | 1.94% | 1.87% |
#19
3
Prev: #16
|
2.8 |
—
|
1,275,000 | 18.1% |
P
S
|
8,300,000 | $83,000,000 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 1.75% | 2.03% |
#20
6
Prev: #14
|
1.2 |
—
|
-625,000 | -15.6% |
P
S
|
3,375,000 | $74,958,750 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NKTR
Nektar Therapeu...
|
Healthcare | 1.63% | 0.57% |
#21
27
Prev: #48
|
3.7 |
—
|
715,000 | 250.9% |
P
S
|
1,000,000 | $69,810,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GMED
Globus Medical ...
|
Healthcare | 1.57% | 1.47% |
#22
2
Prev: #24
|
3.1 |
—
|
239,480 | 39.2% |
P
S
|
850,000 | $67,158,500 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TARS
Tarsus Pharmace...
|
Healthcare | 1.54% | 0.39% |
#23
38
Prev: #61
|
3.6 |
—
|
850,000 | 425.0% |
P
S
|
1,050,000 | $66,087,000 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMTX
Immatics NV
|
Healthcare | 1.46% | 1.70% |
#24
6
Prev: #18
|
1.6 |
—
|
no change | no change |
P
S
|
6,175,000 | $62,552,750 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TRVI
Trevi Therapeut...
|
Healthcare | 1.35% | 0.72% |
#25
19
Prev: #44
|
3.0 |
—
|
933,496 | 43.1% |
P
S
|
3,100,000 | $57,815,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMCR
Immunocore Hold...
|
Healthcare | 1.34% | 2.33% |
#26
14
Prev: #12
|
0.5 |
—
|
-966,868 | -34.9% |
P
S
|
1,800,000 | $57,150,000 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RGEN
Repligen Corp
|
Healthcare | 1.28% | 3.05% |
#27
20
Prev: #7
|
0.5 |
—
|
-525,000 | -56.8% |
P
S
|
400,000 | $54,576,000 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BMY
Bristol-Myers S...
|
Healthcare | 1.08% | 1.70% |
#28
9
Prev: #19
|
0.4 |
—
|
-200,000 | -20.0% |
P
S
|
800,000 | $46,096,000 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
QURE
uniQure NV
|
Healthcare | 1.01% | 0.16% |
#29
44
Prev: #73
|
3.4 |
—
|
576,004 | 160.4% |
P
S
|
935,000 | $43,066,100 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XENE
Xenon Pharmaceu...
|
Healthcare | 0.99% | 1.04% |
#30
4
Prev: #34
|
2.4 |
—
|
60,100 | 9.4% |
P
S
|
700,000 | $42,252,000 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 0.89% | 1.00% |
#31
5
Prev: #36
|
2.4 |
—
|
52,681 | 10.7% |
P
S
|
545,000 | $38,259,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MDGL
Madrigal Pharma...
|
Healthcare | 0.82% | 0.46% |
#32
23
Prev: #55
|
3.3 |
—
|
33,532 | 106.6% |
P
S
|
65,000 | $34,901,750 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALC
Alcon AG
|
Healthcare | 0.78% | 1.69% |
#33
13
Prev: #20
|
0.3 |
—
|
-300,000 | -37.5% |
P
S
|
500,000 | $33,550,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MYGN
Myriad Genetics...
|
Healthcare | 0.77% | 0.21% |
#34
36
Prev: #70
|
3.3 |
—
|
4,087,000 | 248.0% |
P
S
|
5,735,000 | $32,746,850 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RAPP
Rapport Therape...
|
Healthcare | 0.71% | 1.26% |
#35
6
Prev: #29
|
0.3 |
—
|
-706,229 | -49.2% |
P
S
|
730,000 | $30,419,100 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
Crescent Biopha...
|
|
Unknown | 0.69% | 0.77% |
#36
7
Prev: #43
|
2.3 |
—
|
130,000 | 8.7% |
P
S
|
1,630,000 | $29,340,000 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
GEHC
GE HealthCare T...
|
Healthcare | 0.67% | 0.50% |
#37
15
Prev: #52
|
3.3 |
—
|
200,000 | 80.0% |
P
S
|
450,000 | $28,804,500 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
INSM
Insmed Inc
|
Healthcare | 0.62% | — |
#38
Prev: #—
|
3.7 |
—
|
250,000 | — |
NEW
|
250,000 | $26,655,000 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VKTX
Viking Therapeu...
|
Healthcare | 0.62% | 0.83% |
#39
2
Prev: #41
|
0.2 |
—
|
-234,147 | -25.6% |
P
S
|
680,000 | $26,526,800 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBNX
Beta Bionics In...
|
Healthcare | 0.59% | 0.62% |
#40
7
Prev: #47
|
0.2 |
—
|
-611,518 | -27.7% |
P
S
|
1,600,000 | $25,072,000 | 2025 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
REGN
Regeneron Pharm...
|
Healthcare | 0.58% | 0.86% |
#41
2
Prev: #39
|
1.2 |
—
|
no change | no change |
P
S
|
40,000 | $24,941,600 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SLDB
Solid Bioscienc...
|
Healthcare | 0.50% | 1.01% |
#42
7
Prev: #35
|
0.2 |
—
|
-2,840,000 | -56.8% |
P
S
|
2,160,000 | $21,578,400 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 0.48% | 1.30% |
#43
15
Prev: #28
|
0.2 |
—
|
-1,279,075 | -62.0% |
P
S
|
785,000 | $20,716,150 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
First Tracks Bi...
|
|
Unknown | 0.48% | — |
#44
Prev: #—
|
3.7 |
—
|
1,013,000 | — |
NEW
|
1,013,000 | $20,381,560 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
LXEO
Lexeo Therapeut...
|
Healthcare | 0.47% | 0.72% |
#45
Prev: #45
|
0.7 |
—
|
-155,000 | -3.5% |
P
S
|
4,320,000 | $20,109,600 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SVRA
Savara Inc
|
Healthcare | 0.39% | 0.40% |
#46
14
Prev: #60
|
0.7 |
—
|
119,948 | 4.6% |
P
S
|
2,720,000 | $16,755,200 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLTO
Damora Therapeu...
|
Healthcare | 0.35% | 0.43% |
#47
10
Prev: #57
|
0.6 |
—
|
-25,000 | -4.2% |
P
S
|
575,000 | $14,955,750 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
SpyGlass Pharma...
|
|
Unknown | 0.35% | 0.48% |
#48
5
Prev: #53
|
0.6 |
—
|
3,240 | 0.5% |
P
S
|
670,000 | $14,914,200 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
TECX
Tectonic Therap...
|
Healthcare | 0.34% | 0.28% |
#49
15
Prev: #64
|
2.6 |
—
|
97,000 | 29.6% |
P
S
|
425,000 | $14,609,375 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AVTX
Avalo Therapeut...
|
Healthcare | 0.33% | — |
#50
Prev: #—
|
3.6 |
—
|
775,000 | — |
NEW
|
775,000 | $14,322,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 101 holdings